Immune checkpoint inhibitor-related acral vasculitis.

Comont, Thibault; Sibaud, Vincent; Mourey, Loïc; Cougoul, Pierre; Beyne-Rauzy, Odile

Comont, Thibault; Sibaud, Vincent; Mourey, Loïc; Cougoul, Pierre; Beyne-Rauzy, Odile.

Afiliação

Comont T; Service de Médecine Interne, Centre Hospitalier Universitaire Toulouse Purpan - Institut Universitaire du Cancer Toulouse Oncopole, 1 av Joliot-Curie, 31100, Toulouse, France. comont.thibault@iuct-oncopole.fr.
Sibaud V; Service d'Oncodermatologie, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
Mourey L; Service d'Oncologie médicale, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
Cougoul P; Service de Médecine Interne, Centre Hospitalier Universitaire Toulouse Purpan - Institut Universitaire du Cancer Toulouse Oncopole, 1 av Joliot-Curie, 31100, Toulouse, France.
Beyne-Rauzy O; Service de Médecine Interne, Centre Hospitalier Universitaire Toulouse Purpan - Institut Universitaire du Cancer Toulouse Oncopole, 1 av Joliot-Curie, 31100, Toulouse, France.

J Immunother Cancer ; 6(1): 120, 2018 11 16.

Article em En | MEDLINE | ID: mdl-30446009

Assuntos

Antineoplásicos; Melanoma; Neoplasias Cutâneas; Vasculite; Humanos; Ipilimumab

Palavras-chave

Immune check point inhibitors; Immune-related adverse events; Vasculitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Vasculite / Melanoma / Antineoplásicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google